REGN Q3 2021 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.5B+50.5% YoY

Gross Profit

$2.9B84.8% margin

Operating Income

$1.8B53.5% margin

Net Income

$1.6B47.3% margin

EPS (Diluted)

$14.33

QoQ Revenue Growth

-32.8%

Cash Flow

Operating Cash Flow

$3.4B

Free Cash Flow

$3.3B

Stock-Based Comp.

$137M

Balance Sheet

Total Assets

$23.7B

Total Liabilities

$6.4B

Stockholders' Equity

$17.3B

Cash & Equivalents

$3.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.5B	$2.3B	+50.5%
Gross Profit	$2.9B	$2.0B	+49.3%
Operating Income	$1.8B	$1.1B	+75.4%
Net Income	$1.6B	$842M	+93.8%

Revenue Segments

Product

$2.3B66%

Collaboration Revenue

$1.1B31%

Product and Service, Other

$99M3%